In the United States, a drug has been invented that gives hope for slowing down Alzheimer’s disease
[ad_1]
A trial of Donanemab, an experimental drug from Eli Lilly, has shown that it modestly slows the deterioration of memory and thinking in Alzheimer’s disease. Treatment with the drug should be started in the very early stages, which gives hope for slowing down the disease, reports The New York Times. The drug works more effectively on patients younger than 75 years old. A study of 1,736 patients over 18 months showed that in people with early-stage disease, Donanemab slowed the deterioration of memory and thinking by about 4.5 to 7.5 months compared to the effect of a placebo. Photo: lightsource/Depositphotos “Early diagnosis and early intervention are the keys to treating this disease,” says Dr. Daniel Skowronsky, Eli Lilly’s Chief Medical and Scientific Officer. Donanemab is currently under consideration for approval by the Food and Drug Administration (FDA). Earlier, the FDA confirmed the approval of Eisai-Biogen’s Lekembi for the treatment of the disease. Donanemab and Lecambi have not been directly compared to each other in studies, so it is difficult to say which drug may be more effective. However, both drugs have risks of causing swelling and bleeding in the brain. In the Donanemab study, the incidence of edema and bleeding was higher than in the Lekembi study. In clinical trials, three deaths were attributed to Donanemab, and three participants in the Lekembi trials also died after brain swelling and bleeding. However, Eisai said it was unclear whether the drug itself caused the deaths because the patients had complex medical problems None of the drugs reverse or repair the brain damage caused by the disease. That’s why many Alzheimer’s experts see them as just the first step toward fighting the disease. Other experts say the drug slows the disease so little that it’s unclear whether it will be noticeable to patients and their families. Read also: Alcohol consumption can accelerate the development of Alzheimer’s – research
[ad_2]
Original Source Link
